The universal goal for the international HD research focus is to find treatments that reverse, slow or prevent the progression of HD. The Huntington Society of Canada and HD Canadian researchers are a key part of this effort and HSC has a unique role to play.
- Jan. 27, 2022: Novartis community update on the status of the VIBRANT-HD trial, which will test branaplam, an oral huntingtin-lowering drug, in people with Huntington disease. Click here to read more.
- Jan. 18, 2022: Roche announce’s that the tominersen research programme will continue with a new Phase II trial, based on findings from the GENERATION HD1 study in adults with manifest HD. Click here to read more.
- Oct. 20, 2021: Prilenia and Huntington Study Group Announce Completion of Patient Enrollment Ahead of Schedule in Global Phase 3 PROOF-HD Huntington’s Disease Clinical Trial. Click here to read more.
- Feb. 8, 2021: Click here to read a paper that was recently published in the Journal of Clinical Epidemiology based on a series of interviews in which HD community members contributed.
Gene-silencing (otherwise known as huntingtin lowering therapy) offers a promising way to slow or stop Huntington disease (HD). By using anti-sense oligonucleotides (ASOs) to prevent the HD gene from producing huntingtin protein, this approach targets the disease right at its root.
HSC Funded Research
The Huntington Society of Canada is a proud partner of HDBuzz. Launched in early 2011, HDBuzz.net, provides a readable, trusted and up-to-date source for all the latest news on Huntington’s research and clinical trials, written by researchers and scientists specifically for families and individuals affected by HD. This resource is offered in 10 languages and has been well received, currently getting close to 100,000 hits a month.